Clinical effect of Montelukast Sodium in treatment of children with bronchiolitis

Objective To study the effect of Montelukast Sodium in treatment of children with bronchiolitis. Methods A total of 94 cases of children with bronchiolitis in Liangxiang Hospital in Fangshan District of Beijing City from September 2013 to March 2014 were selected and divided into observation group(n=49) and control group(n=45), according to different therapeutic schemes. And the control group was given the general methods of treatment, and the observation group was based on the same treatment plus Montelukast Sodium Tablets. The clinical effect, symptoms disappear time and the incidence of adverse reactions were observed and compared between the two groups. Results The clinical effect between the two groups improved significantly after treatment, the total effective rate in the observation group(93.88%) was higher than that in the control group(82.22%)(P 0.05). ECP levels in the observation group [(9.02±2.37) μg/L] was higher than that in the control group [(5.17±1.09) μg/L](P 0.05); IL-8 levels between the two groups after treatment [(44.68±11.23) μg/L vs(31.19±9.28) μg/L,(50.27±13.30) μg/L vs(28.54±7.37) μg/L] were lower than those before the treatment(P 0.05), but there was no significant difference in two groups after treatment(P 0.05). The symptoms disappear time in the observation group [(5.14±1.16),(4.28±1.31),(3.66±1.09),(4.31±1.47),(7.85± 2.03) d] were less than those in control group [(7.25±1.83),(6.09±1.50),(5.03±1.33),(6.67±1.72),(11.67±2.53) d] after treatment(P 0.05). There were no obvious adverse reactions between the two groups during the treatment. Conclusion The curative effect of Montelukast Sodium Tablets orally in treating capillary bronchitis is significant, with less adverse reactions, which is worthy of clinical promotion and application.